Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Gurnet_Point_Capital
|
| gptkbp:acquisitionYear |
2023
|
| gptkbp:address |
75 Park Plaza, Boston, MA 02116, USA
|
| gptkbp:CEO |
Evan Loh
|
| gptkbp:developedBy |
antibacterial therapeutics
|
| gptkbp:focusesOn |
antibiotic development
|
| gptkbp:founded |
1996
|
| gptkbp:foundedBy |
gptkb:Walter_Gilbert
gptkb:Stuart_Levy |
| gptkbp:headquartersLocation |
gptkb:Boston,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Paratek Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:notableProduct |
gptkb:Sivextro
Nuzyra |
| gptkbp:publiclyTraded |
Yes
|
| gptkbp:researchInterest |
drug-resistant bacterial infections
|
| gptkbp:specializesIn |
tetracycline antibiotics
|
| gptkbp:stockSymbol |
PRTK
|
| gptkbp:website |
https://www.paratekpharma.com/
|
| gptkbp:bfsParent |
gptkb:Aisling_Capital
gptkb:CARIN_Alliance gptkb:NUZYRA |
| gptkbp:bfsLayer |
8
|